Geron Corporation (GERN) : The consensus on Geron Corporation (GERN) based on 4 analyst recommendation on the company stock is 1.5, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 1 which endorses a Strong Buy on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Geron Corporation (GERN) : The most positive equity analysts on Geron Corporation (GERN) expects the shares to touch $10, whereas, the least positive believes that the stock will trade at $5 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $6.67 with an expected fluctuation of $2.89 from the mean.
Also, BTIG Research initiates coverage on Geron Corporation (NASDAQ:GERN). The rating major has initiated the coverage with neutral rating on the shares. The rating by the firm was issued on August 19, 2016.
Geron Corporation (NASDAQ:GERN): The stock opened in the green at $2.06 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $2.11 and a low of $1.94 for the day. The stock did not find buyers even at the lows and closed at $1.97 recording a loss of -4.83%. 3,943,743 shares exchanged hands during the trading day. The stock had closed at $2.07 in the previous days trading.
Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.